<mods:mods version="3.3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mods="http://www.loc.gov/mods/v3"><mods:titleInfo><mods:title>ALLERGIK OFTALMOPATOLOGIYALARDA OLOPATADIN GIDROXLORID 0.1% TARKIBLI KO’Z TOMCHISINI SAMARADORLIGINI BAHOLASH</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">Sarvarxon</mods:namePart><mods:namePart type="family">Yuldashov</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Abdulxamid</mods:namePart><mods:namePart type="family">Sodiqov</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>Butun jahon sog’liqni saqlash tashkiloti (BJSST) tomonidan oxirgi 10 yil davomida o’tkazilgan epidemiologik tadqiqotlar statistik xulosasi, allergik kasalliklar chastotasining global o'sishini qayd etdi [1,7,13]. Jahon allergiya tashkiloti (JAT)ning rasmiy bayonotiga ko’ra, hozirda umumiy allergozlar miqdori 3 barobar, xususan allergik oftalmopatologiyalar uchrashi 25% gacha ko’paygan [2,4]. Allergik ko'z kasalliklarining immunopatogenetik asosini gistamin (H) retseptorlari faollashishi va semiz hujayralarning degranulyatsiyasi tashkil qiladi [5,9,12]. Ushbu maqolaning asosiy maqsadi – oftalmologiya amaliyotida nisbatan yangi topikal antiallergik preparat - olopatadin gidroxlorid (Olopatadin 0.1% ko'z tomchisi) bo'yicha mavjud ilmiy adabiyotlarni ko'rib chiqish va tahlil qilish, shuningdek, klinik tadqiqot orqali Olopatadin 0.1% eritmasi preparatining samaradorligini baholash.</mods:abstract><mods:originInfo><mods:dateIssued encoding="iso8601">2024-10-14</mods:dateIssued></mods:originInfo><mods:genre>Maqola</mods:genre></mods:mods>